<DOC>
	<DOCNO>NCT00298038</DOCNO>
	<brief_summary>The purpose study determine study drug safe effective prevent Hepatic Encephalopathy ( HE ) .</brief_summary>
	<brief_title>A 6-month Efficacy , Safety Tolerability Study Rifaximin In Preventing Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Must sign Informed Consent Form In remission past hepatic encephalopathy ( HE ) . Appropriate birth control measure More equal 18 year age . Must potential benefit treatment . Recent prior HE episodes Capable willing comply study procedure . Subject personal support available Has certain Model End Stage Liver Disease ( MELD ) score Recent TIPS placement revision Significant medical condition , medical condition may impact study participation , Investigator decision include . Allergies study drug similar drug . Laboratory abnormality . Recent participation another clinical trial History noncompliance Pregnant risk pregnancy , lactate . Recent alcohol consumption Active bacterial viral Infections Bowel issue Active malignancy . On prohibited medication . Liver transplant expect near term Lactulose intolerance Subject show presence intestinal obstruction inflammatory bowel disease . Ongoing recent GI bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>